CEI Banner

Editor's Choice


NK Cells
Clinical & Experimental Immunology

In CEI, we continue our interest in NK cells with a review by Moretta et al. discussing new information relating to the molecular basis of successful haploidentical haematopoietic stem cell transplantation (haplo-HSCT). As mentioned above, NK cells are capable of killing cancer cells and recent clinical data from haplo-HSCT has revealed NK cells are responsible for highly favourable effects in both adult and paediatric high-risk leukaemias. The authors discuss the role of the HLA class I-specific Killer Immunoglobulin-like Receptors (KIR) and alloreactive NK cells in successful haplo-HSCT in patients with high-risk leukaemias. 
Cancer Therapy 
Clinical & Experimental Immunology

Continuing on the theme of cancer therapy, Martinelli et al. discuss the mechanisms of epidermal growth factor receptor (EGFR)-specific monoclonal antibodies in cancer therapy.  EGFR, a transmembrane tyrosine kinase receptor, is the first molecular target against which monoclonal antibodies have been developed for cancer therapy. The authors focus on two recently introduced EGFR monoclonal antibodies, cetuximab and panitumumab, designed for the treatment of metastatic colorectal and, head and neck cancer.

View the Archive